TFAP2A

Across TCGA pan-cancer cohorts, TFAP2A RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TFAP2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TFAP2A RNA is repressed in tumor relative to normal tissue. In most cancer types TFAP2A is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, HNSC, and COAD are the cancer types where TFAP2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TFAP2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	−2.411	<.001	12	view →
HNSC	Male	All	+1.231	<.001	12	view →
COAD	All	III,IV	+1.549	<.001	11	view →
LUAD	Male	II,III,IV	+2.502	<.001	9	view →
LUSC	All	III,IV	+4.146	<.001	8	view →
STAD	All	IV	+2.696	<.001	8	view →
UCEC	All	All	+3.427	<.001	6	view →
BLCA	Male	All	+2.561	<.001	6	view →
READ	Male	All	+1.393	.003	6	view →
BRCA	All	II,III,IV	+1.246	<.001	6	view →
LIHC	All	All	+0.300	.003	4	view →
CHOL	Male	All	+3.931	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TFAP2A–KIRC

Open the KIRC breakdown →